14 Dec 2021
Kenox Pharmaceuticals announces successful completion of a pre-IND meeting with the US-FDA for its lead program KNX018 – a novel inhaled drug-device combination product as an adjunct sensitizer for radiation therapy in NSCLC patients
Author: admintech | Filed under: Press ReleasePRINCETON, N.J., Dec. 14, 2021 /PRNewswire/ — Kenox Pharmaceuticals Inc, a privately owned pharmaceutical company focused on respiratory drug products, has submitted Type B Pre-Investigational New Drug (IND) meeting request with the U.S. Food and Drug Administration (FDA) for its lead…